Clinical Trial

A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight

Study acronym: TRIUMPH-2
Completed Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to is to evaluate the efficacy and safety of retatrutide in participants with type 2 diabetes in participants who have obesity or overweight (J1I-MC-GZBK master protocol) including a subset of participants who have obstructive sleep apnea (OSA) (J1I-MC-GSA2). The study will last about 89 weeks and will include up to 24 visits.
Protocol Amendment History 4 changes
critical Trial completed 2026-07-31
notable Enrollment increased: 1000 -> 1152 participants 2026-07-31
notable Primary completion pushed: 2026-05 -> 2026-06-16 2026-07-31
minor Completion pushed: 2026-05 -> 2026-06-16 2026-07-31
Trial Details
NCT Number NCT05929079
Lead Sponsor Eli Lilly and Company
Conditions Type 2 Diabetes, Obesity, Overweight, Obstructive Sleep Apnea
Enrollment 1,152 participants
Start Date 2023-07-11
Primary Completion 2026-06-16 (estimated)
Study Completion 2026-06-16 (estimated)
Updated on ClinicalTrials.gov 2026-07-30